Copy

June 2024

In this Sector Update

Haere rā from Anne

Zero-fees update

NCSP coverage update

Testing after cancer

Clinical practice tips

News from around the motu

Remembering Talei Morrison


Continuation of zero-fees for priority groups

To support the initial launch of HPV primary screening in September 2023, Health New Zealand | Te Whatu Ora announced funding to expand the delivery of zero-fees screening to priority groups. This was an initial step in place until 30 June 2024.  


The National Cervical Screening Programme (NCSP) has worked with a sector funding design group to develop a new funding model that will reduce cost barriers and improve access to cervical screening for groups with the greatest need.  The sector group involved in developing this funding model included a range of participants from general practices, Primary Health Organisations, Hauora Māori Providers, Support to Screening Providers, and other organisations.  


We can now confirm funding has been extended from 1 July 2024.


The priority group definition has not changed and remains all women and people with a cervix who are un-screened or under-screened, all wāhine and whānau with a cervix who are Māori and Pacific, those who hold a community services card (CSC), and anyone who requires follow-up testing.  


These groups are eligible for zero-fees screening because they experience higher rates of cervical cancer, or face cost barriers to screening.


The updated prices and structure came into effect on 1 July 2024.


For more information about the new zero-fees funding model, who is eligible for zero-fees screening, and prices click here.  


NCSP coverage

There is a visible impact on the reporting of screening coverage for the National Cervical Screening Programme (NCSP) due to the annual population projections update.


Each year, Statistics New Zealand update population projections. The population update has been of greater significance than prior years, as net migration has grown significantly in 2023 with the re-opening of the New Zealand border.


Population information forms the denominator for our cancer screening programmes. The change to the denominator will impact both positively and negatively on our programme coverage reporting.


Summary of the updated population projections and resulting changes to the NCSP coverage rates:

  • The most recent national cervical screening coverage rate is approximately 1.9 percent lower than previously reported, after applying the updated 2023 population projections.

  • A decrease in the projected Māori population means Māori cervical screening coverage is 0.2 percent higher than previously reported.

  • A decrease in the projected Pacific population means that Pacific cervical screening coverage is 1.4 percent higher than previously reported.

  • An increase in the projected Asian population group means Asian cervical screening coverage is 9 percent lower than previously reported.

  • An increase in the projected Other population means Other cervical screening coverage is 0.2 percent lower than previously reported.

  • All Districts have had changes in population in the updated 2023 population projections. This has been reflected with a decline in overall coverage from 4.1 percent (Auckland) up to a 1.7percent increase in coverage (Wairarapa) compared to what has been previously reported.

  • Some Districts with smaller populations of ethnicities will see larger differences in coverage than if the projections had not been applied, particularly for coverage for Pacific and Asian women and people with a cervix. For example, Northland District Pacific Peoples population decreased by 21.9 percent, resulting in an increase in coverage by 12.8 percent compared to what was previously reported.


The 2023 population projections have been updated on the NCSP R-shiny coverage app: https://tewhatuora.shinyapps.io/nsu-ncsp-coverage/. The 2023 population projection updates will be applied consistently to all time periods, including the April 2024 data.

Testing after cancer

HPV and cytology testing following treatment for cervical and vaginal cancer is not screening. Because of this, anyone with cervical or vaginal cancer was unenrolled from the previous NCSP Register and communications were turned off.  


For people who have had early-stage cervical cancers which have been treated by:

  • local excision (i.e. LLETZ): these participants will return to regular cervical screening after successful treatment and completion of a Test of Cure.  

  • a total hysterectomy: these participants can cease cervical screening after completing a Test of Cure.


With the exception of the above groups, the NCSP will automatically unenroll anyone with a history of cervical or vaginal cancer and will not be making recommendations on tests received for this group.  


For those who are unenrolled because of previous cancer, there are no restrictions on continuing to have HPV or cervical cytology tests. This should be determined by the clinician and the participant. Labs will no longer give recommendations for further screening when reporting these tests.  


Women with gynaecological cancers who have had a sub-total hysterectomy need to continue screening,and will continue to receive notifications from the Register.


Some participants who had previously ceased screening after an early-stage cancer in the previous programme may now be recommended to return to screening or to complete a Test of Cure. These participants will receive reminders from the NCSP and will be included in the PHO Cervical Screening Status Report.  

Practice tips

Testing in the presence of symptoms

Screening tests are for people who are asymptomatic. Where there are clinical symptoms (Bleeding - intermenstrual, post coital, post menopause pain or discharge) an LBC for co-testing with both HPV and cytology is often appropriate as part of the clinical assessment. Inappropriate co-testing however is discouraged as it can use valuable health resources, so laboratories have been provided with the following instructions:


LBC samples: Accept requests for co-testing if the following symptoms/signs are recorded on the laboratory request form:


1.     Abnormal vaginal bleeding of any type

2.     An abnormal appearance of the cervix or vagina

3.     Pelvic Pain

4.     Vaginal discharge


LBC samples: Decline cytology testing if co-testing has been requested and the HPV result is Not Detected, if the request form states:


1.“Clinically indicated”

2. “Symptoms” (not otherwise specified)

3.  Friable cervix

4.  Contact bleeding


Where the HPV result is Detected,the laboratory will process cytology or refer the participant for specialist assessment according to the NCSP Clinical Practice Guidelines


Cytology will not be processed for an asymptomatic person (no symptoms or signs recorded on the request form) if the HPV result is Not Detected


LBC samples are kept for one month so if a referrer omitted to write the indication for co-testing on the form and only an HPV test is processed, the referrer can ring the laboratory to provide the reason for requesting co-testing,and the laboratory will then process the cytology


Swab samples: Participants will be recalled for cytology if the result is HPV Not Detected and the following is recorded on the request form:

  1. Abnormal vaginal bleeding, any type.

  2. An abnormal appearance of the cervix or vagina


If co-testing is required, please SUBMIT AN LBC SAMPLE ONLY. Both HPV and cytology can be processed from an LBC sample. Don’t send a vaginal swab as well– it isn’t required and will be discarded at the laboratory if both an LBC and swab sample are sent.


Anyone with symptoms should be fully clinically assessed, usually including a clinical examination. Co-testing is only one part of the assessment, and negative results will not necessarily exclude significant cervical pathology.


Please refer to your local Health Pathways for advice regarding the assessment and management of those with symptoms.


Reporting a person’s hysterectomy status

Clinicians may be aware that some people have had a hysterectomy which is not recorded on the NCSP Register.  


You can inform the NCSP Register about a person’s hysterectomy status using the updated form on the Health NZ – Te Whatu Ora website here.  


If the hysterectomy is not recorded on the new NCSP Register, people maybe receiving notifications or appearing on the cervical screening status report as overdue for cervical screening. This could also be happening because they still require some screening or follow up even though they have had a hysterectomy.  


Updating ethnicity

Please note for bowel, breast and cervical screening purposes the ethnicity must be updated on the NHI to update the screening registers.  It is not sufficient to solely update on the Patient Management System as this does not automatically update NHI data. The process for updating NHI varies between PMS. Please consult your administration staff for assistance.


Please email ncsp@tewhatuora.govt.nz if you are aware of any similar situations among people you have screened, or if there are any other unexpected reactions you are aware of. This will enable the NCSP to continue its monitoring and update advice as required.


Recalls and Reminders

It’s important to continue to send recalls and reminders to your patients at a local level. 


The NSU website has moved to Health NZ

The National Screening Unit (NSU) website has been decommissioned and its content moved to Health New Zealand | Te Whatu Ora (Health NZ) centralised websites.


The NSU URL address will still work and if you have used this URL in any resources or materials,the URL will redirect through to the Health NZ website or the Health Information and Services website. We encourage you to please update, over time, any resources where the current NSU URL is used with the appropriate Health NZ website.


Why this change?

Health NZ has operated many health websites, such as NSU and TimetoScreen, this is causing confusion for audiences as they don’t know where to go for trusted online health information. Centralising and unifying health information allows Health NZ to improve the overall user experience and ensure health information still is prompt, consistent, and reliable for whānau and communities.


Time to Screen website

The TimetoScreen website will also be transitioning over to the Health Information and Services website on July 16. The timetoscreen.nz URL will remain and will redirect to the Health Information and Services site indefinitely.



Remembering Talei Morrison

June 16 marked 6 years since Talei Morrison, courageous founder of the Smear Your Mea campaign passed away from cervical cancer in 2018. Talei was a phenomenal wāhine, Kapa Haka star,educator, mother and much more.  In an effort to raise awareness of the disease and to stop other wāhine having to go through what she did, Morrison launched the Smear Your Mea campaign.  Her journey remains as a strong emotive kaupapa and legacy that holds significant resonance with wāhine and whanau across the motu.


Talei Morrison

Talei Morrison

Introducing Cindy Dargaville, NCSP Manager

Cindy Dargaville has been appointed to the role of Manager, National Cervical Screening Programme starting, 1 July 2024.


The National Cancer Screening programmes welcomes Cindy’s vast experience and proven track record in; hauora and cancer leadership, Māori health equity, advocacy, research, operational management,and strategy.


We very much look forward to Cindy leading the Cervical Screening component of the Cervical Cancer elimination strategy,embedding of the Primary Human Papillomavirus (HPV) screening programme, and bringing her mana, strong sector relationships, strategic and programme leadership.


Cindy has most recently been the CEO of Hei Āhuru Mowai, Māori Cancer Leadership Aotearoa.


Cindy Dargaville on the left and Mary-Ann Clueard on the right

Kia ora from Mary-Ann Clueard

In June we welcomed Mary-Ann Clueard to the NCSP as Senior Relationship Manager.


Based in Whangarei, Mary-Ann’s primary focus is supporting kaimahi across the motu delivering screening and support services as well as developing and strengthening relationships with primary care. We asked Mary-Ann in her own words, to share a little about where she’s from and what she cares about.


“Bornin Tāmaki Makaurau, to a Scottish born father and a Te Waipounamu born mother who whakapapa’s to Ngāi Tahu, I am married to Damian who whakapapa’s to Ngāpuhi and was born and bred in Tai Tokerau.  We have 2 human daughters Amber (28) and Riley (19) and 2 furry doggie children.


I am a Registered Nurse and have a background in aged care, acute medical and over a decade in primary care.


Over the years I have been a nurse manager and had the privilege of working in a PHO role as a general practice services lead in Tai Tokerau.  From 2021 I was able to be involved in research that was looking at the feasibility of the HPV self-test in Tai Tokerau, this helped provide information and evidence towards the new HPV primary screening programme in Aotearoa.  


I am incredibly passionate about cervical screening and most importantly the new HPV primary screening programme.  Being able to help wāhine access screening in a way that is more acceptable to them is so important for me and my whānau. Especially as my closest and dearest friend was diagnosed with HPV related cervical cancer.  At the time this was a very new type of diagnosis, and she would have had less interventions if she had screened on time and even had HPV screening.  Gratefully she has survived and is a huge supporter of the HPV immunisation and screening programmes.  Hence, I am very passionate about continuing to ensure we are screening our wāhine on time, with an acceptable screening programme.”  Contact Mary-Ann on: Mary-ann.Clueard@TeWhatuOra.govt.nz


News from your region?

We love sharing news and photos of your awesome mahi out and about in the community.Please send to us at: hpvscreen@tewhatuora.govt.nz.


Health New Zealand - Te Whatu Ora
133 Molesworth Street, Thorndon
hpvscreen@tewhatuora.govt.nz
tewhatuora.govt.nz